-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewNet Present Value Model: Actinium Pharmaceuticals Inc’s Iomab B
Empower your strategies with our Net Present Value Model: Actinium Pharmaceuticals Inc's Iomab B report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabatolimab in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabatolimab in Myelofibrosis Drug Details: Sabatolimab is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Chronic Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-036C in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-036C in Solid Tumor Drug Details: MHB-036C is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-036C in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-036C in Endometrial Cancer Drug Details: MHB-036C is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Multiple Myeloma...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Diffuse Large...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Follicular Lymphoma Drug Details:...